

Financial news for RGLS dated on 2020-05-14: Regulus Therapeutics Q1 EPS \$(0.250) Up From \$(0.310) YoY

Financial news for RGLS dated on 2020-05-13: Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.

Financial news for RGLS dated on 2020-05-04: HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Lowers Price Target to \$1.5

Financial news for RGLS dated on 2020-03-12: Regulus Therapeutics Q4 EPS \$(0.23) Up From \$(0.98) YoY

Financial news for RGLS dated on 2020-02-13: Regulus Therapeutics Reinitiates Multiple Ascending Dose Study Of RGLS4326 For The Treatment Of ADPKD

Financial news for RGLS dated on 2019-12-16: Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326

Financial news for RGLS dated on 2019-11-12: Regulus Therapeutics Q3 EPS \$(0.26) Up From \$(1.18) YoY, Sales \$18K, Same YoY

Financial news for RGLS dated on 2019-09-06: Regulus Therapeutics shares are trading higher after H.C. Wainwright initiated coverage on the stock with a Buy rating and a price target of \$2 per share.

Financial news for RGLS dated on 2019-09-06: H.C. Wainwright Initiates Coverage On Regulus Therapeutics with Buy Rating, Announces \$2 Price Target

Financial news for RGLS dated on 2019-08-08: Regulus Therapeutics shares are trading higher after the company reported Q2 EPS and sales are up from the same quarter last year.

Financial news for RGLS dated on 2019-08-08: Regulus Therapeutics Q2 EPS \$(0.3) Up From \$(1.59) YoY, Sales \$18K, Same YoY

Financial news for RGLS dated on 2019-05-17: Regulus Therapeutics 13G By Altium Capital Mgmt. Shows New 9.99% Stake

Financial news for RGLS dated on 2019-05-09: Regulus Therapeutics Q1 EPS \$(0.31) Beats \$(1.15) Estimate, Sales \$6.778M Beat \$10K Estimate

Financial news for RGLS dated on 2019-05-06: Regulus Therapeutics Announces Restructuring Of Term Loan

Financial news for RGLS dated on 2019-03-18: Regulus Therapeutics Q4 EPS \$(0.98) Misses \$(0.92) Estimate, Sales \$18K Miss \$3.51M Estimate

Financial news for RGLS dated on 2019-01-09: European Patent Office Documents Show Patent Related To Hepatitis C Awarded To Regulus Therapeutics

Financial news for RGLS dated on 2019-01-07: Regulus Announces Nomination Of RGLS5579 For Treatment Of Glioblastoma Multiforme

Financial news for RGLS dated on 2019-01-04: Regulus To Submit Comprehensive Data Package For RGLS4326 To FDA; Co. Previously Had Paused The Study Due To Unexpected Observations, No Adverse Or Other Significant Findings To Date

Financial news for RGLS dated on 2018-12-12: Regulus Therapeutics Filing Shows Registration For \$20M Common Stock Offering

Financial news for RGLS dated on 2018-11-27: Hearing Regulus Therapeutics Granted US Patent '484 For 'targeting microRNAs for metabolic disorders'

Financial news for RGLS dated on 2018-11-19: Regulus Therapeutics Presents New Data on its Novel Treatment for Glioblastoma Multiforme

Financial news for RGLS dated on 2018-11-16: Regulus Therapeutics 8-K Shows Co. Received Notice From Nasdaq The Co.'s Shareholders' Equity Reported On 1-Q For Qtr. Ended Sep. 30, 2018 Does Not Satisfy Continued Listing Requirement

Financial news for RGLS dated on 2018-11-09: Stocks Which Set New 52-Week Low Yesterday, Thurs., Nov. 8, 2018

Financial news for RGLS dated on 2018-11-08: Regulus Therapeutics Q3 EPS \$(1.18) Beats \$(1.25) Estimate, Sales \$18K Beat \$10K Estimate

Financial news for RGLS dated on 2018-11-07: Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Wed., Nov. 7, 2018

Financial news for RGLS dated on 2018-11-07: Wedbush On Regulus Therapeutics: Sees 'limited upside potential until safety concerns for RGLS4326 are mitigated by new 27-week mouse toxicity data in H1:19'

Financial news for RGLS dated on 2018-11-06: Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Nov. 6, 2018

Financial news for RGLS dated on 2018-11-06: Regulus Licenses miR-21 to Sanofi for \$7M Upfront and Up to \$40M in Development Milestones

Financial news for RGLS dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for RGLS dated on 2018-10-24: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Wed., Oct. 24, 2018

Financial news for RGLS dated on 2018-10-23: Regulus Therapeutics shares are up 58.5% on heavy volume following a Monday press release announcing the company will present preclinical data on RGLS4326 for kidney disease at the American Society of Nephrology on Oct. 25.

Financial news for RGLS dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for RGLS dated on 2018-10-22: Regulus Therapeutics Shares Up 42% On Heavy Volume (~196K Shares) Following Co. Press Release Previewing Will Present Preclinical Data On RGLS4326 In Development For Autosomal Dominant Polycystic Kidney Disease At American Society of Nephrology Oct. 25

Financial news for RGLS dated on 2018-10-18: Regulus Regains Compliance with NASDAQ Listing Requirements

Financial news for RGLS dated on 2018-10-05: Stocks Which Set New 52-Week High Yesterday, October 4th

Financial news for RGLS dated on 2018-10-04: Regulus Therapeutics Reports 1-For-12 Reverse Stock Split, Effective Oct. 4

Financial news for RGLS dated on 2018-08-15: Stocks Which Set New 52-Week Low Yesterday, August 14th

Financial news for RGLS dated on 2018-08-09: Regulus Therapeutics Q2 EPS \$(0.13) Beats \$(0.16) Estimate

Financial news for RGLS dated on 2018-08-09: Stocks Which Set New 52-Week Low Yesterday, August 8th

Financial news for RGLS dated on 2018-07-31: Stocks Which Set New 52-Week Low Yesterday, July 30th

Financial news for RGLS dated on 2018-07-30: Stocks Which Set New 52-Week Low Friday, July 27

Financial news for RGLS dated on 2018-07-10: Wedbush Downgrades Regulus Therapeutics to Neutral

Financial news for RGLS dated on 2018-07-06: Regulus Therapeutics Shares Down 38.5% Premarket After Co. Late Thursday Announced Restructuring And 60% Workforce Reduction

Financial news for RGLS dated on 2018-07-05: Regulus Therapeutics Shares To Resume Trade At 5:30 p.m. EDT

Financial news for RGLS dated on 2018-07-05: UPDATE: Regulus Says Its Seeking To Partner For The Balance Of Its Preclinical Programs

Financial news for RGLS dated on 2018-07-05: UPDATE: Regulus Sees Filing Investigational New Drug Application For HBV Program In 2H'19

Financial news for RGLS dated on 2018-07-05: UPDATE: Regulus Says Co. Determined Advancing Preclinical Programs Targeting HBV Represented Most Attractive Opportunity In Its Pipeline For Investment

Financial news for RGLS dated on 2018-07-05: UPDATE: Regulus Offers Pipeline Update: Prelim. Results From First Patients Of RG-012 For Treatment Of Alport Syndrome: Kidney Tissue Concentrations Achieved Would Be Predictive Of Benefit Based On Animal

Models, Modulation Of miR-21 Observed

Financial news for RGLS dated on 2018-07-05: Regulus Announces Strategic Update, Pauses Recruitment Activities For Its RG-012 Program In Alport Syndrome

Financial news for RGLS dated on 2018-07-05: Regulus Therapeutics Shares Halted News Pending

Financial news for RGLS dated on 2018-05-10: Regulus Therapeutics Q1 EPS \$(0.15) Misses \$(0.14) Estimate, Sales \$18K, Same YoY

Financial news for RGLS dated on 2018-05-01: Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD

Financial news for RGLS dated on 2018-05-01: Regulus Therapeutics Reports Initiation Of Multiple Ascending Dose Study In Healthy Volunteers Of RGLS4326 For Treatment Of ADPKD

Financial news for RGLS dated on 2018-03-28: B. Riley Initiates Coverage On Regulus Therapeutics with Neutral Rating, Announces \$1.00 Price Target

Financial news for RGLS dated on 2018-03-07: Regulus Therapeutics Reports Q4 EPS \$(0.14) vs \$(0.16) Est.

Financial news for RGLS dated on 2018-01-05: Leerink Swann Initiates Coverage On Regulus Therapeutics with Outperform Rating, Announces \$2.00 Price Target

Financial news for RGLS dated on 2017-12-19: Regulus Reports First-in-Human Dosing for Phase I Study of RGLS4326

Financial news for RGLS dated on 2017-11-08: BMO Capital Maintains Market Perform on Regulus Therapeutics, Lowers Price Target to \$1.00

Financial news for RGLS dated on 2017-11-07: Regulus Therapeutics Reports Q3 EPS \$(0.18) vs \$(0.16) Est., Sales \$18K vs \$860K Est.

Financial news for RGLS dated on 2017-08-02: Chardan Capital Downgrades Regulus Therapeutics to Neutral

Financial news for RGLS dated on 2017-08-01: Regulus Reports Q2 EPS \$(0.41) vs \$(0.33) Est., Sales \$18K vs \$87K Est.

Financial news for RGLS dated on 2017-07-24: 13G Filing From Broadfin Capital On Regulus Therapeutics Shows 5.65% Stake

Financial news for RGLS dated on 2017-07-19: Regulus Announces Common Stock Offering, No Size Disclosed

Financial news for RGLS dated on 2017-06-13: Regulus Names Dr. Mark Deeg Chief Medical Officer

Financial news for RGLS dated on 2017-06-12: Regulus Announces Pipeline Updates

Financial news for RGLS dated on 2017-06-08: Aptuit Reports Strategic Provider Agreement with Regulus Therapeutics For Range Of Discovery and Non-Clinical Services

Financial news for RGLS dated on 2017-05-04: Regulus Shares to Resume Trade at 5 p.m. EDT

Financial news for RGLS dated on 2017-05-04: Regulus Says It Has Completed Dosing Of RG-012 In Phase 1 Study, Prelim Data Show RG-012 Well Tolerate

Financial news for RGLS dated on 2017-05-04: Regulus Reports Q1 EPS \$(0.38) vs \$(0.35) Est., Sales \$18K vs \$940K Est.

Financial news for RGLS dated on 2017-05-04: Regulus Shares Halted News Pending

Financial news for RGLS dated on 2017-03-29: Wedbush Reiterates Outperform On Regulus Therapeutics, Maintains \$6 Price Target

Financial news for RGLS dated on 2017-03-07: Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio

Financial news for RGLS dated on 2017-03-06: Wedbush Reiterates Outperform On Regulus Therapeutics, Lowers Price Target To \$6

Financial news for RGLS dated on 2017-03-02: Regulus Reports Q4 EPS \$(1.55) May Not Compare To \$(0.37) Est., Sales \$18K May Not Compare To \$920K Est.

Financial news for RGLS dated on 2017-02-15: Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma

Financial news for RGLS dated on 2017-01-30: Wedbush Maintains Outperform on Regulus Therapeutics, Lowers Target from \$13 to \$8.00

Financial news for RGLS dated on 2017-01-30: Needham Downgrades Regulus Therapeutics To Hold

Financial news for RGLS dated on 2017-01-30: Wells Fargo Downgrades Regulus Therapeutics To Market Perform

Financial news for RGLS dated on 2017-01-27: Regulus Therapeutics Shares Halted News Pending

Financial news for RGLS dated on 2016-12-16: Cantor Fitzgerald Initiates Coverage On Regulus Therapeutics at Overweight, Announces \$11.00 Target

Financial news for RGLS dated on 2016-06-28: BMO Capital Downgrades Regulus Therapeutics to Market Perform

Financial news for RGLS dated on 2016-06-07: Chardan Capital Maintains Buy on Regulus Therapeutics, Raises PT from \$15 to \$20 in Mid-Day Note

Financial news for RGLS dated on 2016-04-13: Chardan Capital Initiates Coverage on Regulus Therapeutics at Buy, Announces \$15.00 PT

Financial news for RGLS dated on 2016-04-12: BMO Capital Initiates Coverage on Regulus Therapeutics at Outperform, Announces \$16.00 PT

Financial news for RGLS dated on 2015-12-04: Wells Fargo Initiates Coverage on Regulus Therapeutics at Outperform

Financial news for RGLS dated on 2015-06-08: Guggenheim Securities Initiates Coverage on Regulus Therapeutics at Buy

Financial news for RGLS dated on 2015-06-04: Regulus Initiates Phase I Clinical Study of RG-012, a microRNA Therapeutic in Development for the Treatment of Alport Syndrome

Financial news for RGLS dated on 2015-04-25: Regulus Announces RG-101 Achieves Sustained HCV Viral Suppression with Favorable Safety and Tolerability

Financial news for RGLS dated on 2015-04-21: FBR Capital Initiates Coverage on Regulus Therapeutics at Outperform, Announces \$30.00 PT

Financial news for RGLS dated on 2014-11-24: Deutsche Bank Initiates Coverage on Regulus Therapeutics at Buy, Announces \$30.00 PT

Financial news for RGLS dated on 2014-11-05: Regulus Therapeutics Reports Q3 EPS of \$(0.26) vs \$(0.23) Est; Revenue of \$1.10M vs \$2.59M Est

Financial news for RGLS dated on 2014-10-28: Regulus Prices 5,294,118 Share Offering @ \$17.00/Share

Financial news for RGLS dated on 2014-10-22: A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment History

Financial news for RGLS dated on 2014-08-05: Regulus Enters New Collaboration Agreement with Biogen; Regulus to Receive \$2M Upfront with Potential Future Milestone Payments

Financial news for RGLS dated on 2014-05-08: Regulus Therapeutics Reports Q1 EPS of \$(0.30) vs \$(0.14) Est; Revenue of \$1.60M vs \$4.10M Est

Financial news for RGLS dated on 2014-02-27: Regulus Therapeutics Reports Q4 EPS of \$(0.11) vs \$(0.13) Est; Revenue of \$5.45M vs \$4.08M Est

Financial news for RGLS dated on 2013-11-13: Regulus Therapeutics Reports Q3 EPS of \$(0.07) vs \$(0.15) Est; Revenue of \$6.12M vs \$3.51M Est

Financial news for RGLS dated on 2013-08-14: Lazard Capital Markets Maintains Buy on Regulus Therapeutics, Raises PT to \$15.00

Financial news for RGLS dated on 2013-02-20: Regulus Therapeutics Reports Q4 EPS of

\$(0.22) vs \$(0.07) Est; Revenue of \$3.24M vs \$3.30M Est

Financial news for RGLS dated on 2012-11-29: Wedbush Securities Initiates Coverage
Regulus Therapeutics With an Outperform Rating, Announces PT of \$10.0